stoney i forget if you have sofi on your spac top five list... don't know much about it except it was on my watch list and climbed to prior highs this week (50% climb since mid-may) based on completing its merge.
How many open positions comprise new entries you've made in the prior week, month? What's your-all's target hold time for most of the entries you take in general, days, weeks, months? Thanks.
RE: Purecycle Technologies Inc it's funny, every single chart i've looked at lately has that bottom at May 13 and then a 30%+ climb since then. purecycle looks like it's climbed 80% but wow it had a real bottom on May 13th. I guess around May 6th a short seller report trashed it. https://hindenburgresearch.com/purecycle/ i dunno stoney, some of these save-the-earth plastic companies will probably end up doing well eventually but i think you have to buy the true bottom on this stuff right now
stoney will have to jump in and explain the concept of the phantasma or the stages of a flowering plant or...
Check it out this morning.... CAMBRIDGE, Mass. — (BUSINESS WIRE) — June 7, 2021— bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of LentiGlobin for sickle cell disease (SCD) gene therapy (bb1111) for adult and pediatric patients with SCD, and the Phase 3 Northstar-2 (HGB-207) and Northstar-3 (HGB-212) studies of betibeglogene autotemcel gene therapy (beti-cel; licensed as ZYNTEGLO™ in the EU and the UK) for adult, adolescent and pediatric patients with transfusion-dependent β-thalassemia (TDT). The company is working closely with study investigators and clinical trial sites to resume all study activities as soon as possible. “Patient safety continues to be our utmost priority, and we are grateful for the close partnership with the FDA, investigators, scientists and most importantly, patients, who all contributed to the assessments of the adverse events in HGB-206 that ultimately led to today’s announcement,” said Andrew Obenshain, president, severe genetic diseases, bluebird bio. “As pioneers in gene therapy, we remain committed to advancing the field through our learnings. Over the past four months, we have gained deeper knowledge and understanding of the pathophysiology of sickle cell disease that will allow us to better serve patients and the broader community. We look forward to resuming our clinical programs and continuing to advance toward major regulatory submissions for sickle cell disease and β-thalassemia.” Previously Reported Safety Events On March 10, 2021, bluebird bio reported that it is very unlikely the suspected unexpected serious adverse reaction (SUSAR) of acute myeloid leukemia (AML) reported in the HGB-206 study of LentiGlobin for SCD was related to the BB305 lentiviral vector (LVV). No cases of hematologic malignancy have been reported in any patient who has received treatment with beti-cel. On April 20, 2021, bluebird bio announced a revised diagnosis for the previously reported case of myelodysplastic syndrome (MDS) in its Phase 1/2 study of LentiGlobin for SCD. Upon further assessment, the treating investigator concluded this is not a case of MDS and revised the diagnosis to transfusion-dependent anemia.
market seemed to like Iovance's ASCO presentation: IOVA Iovance Biotherapeutics Inc 19.18 USD+1.25 (7.00%)
$34.50 on the pre-market but don’t understand why is difficult to maintain the price during the session.
surprised to see it still going...i sold a little early on this one. IOVA Iovance Biotherapeutics Inc 20.18 USD+2.26 (12.61%)
Stoney! $WSC $29 Pricey by any fundamental metric, but a great backdoor on any and all construction/infrastructure spending. Starting to get some mainstream press too. Looks like its poised for a near-term pop. I think they present somewhere tomorrow too. Edit: Stifel Cross Sector Insight Conference on 6/9 These things are everywhere and tbh, they are the first thing on any large job-sight and the last thing to leave. Good (short-term) long play, stop at $27.40